Floatz logo

Risdiplam

Muscular Atrophy, Spinal

Scholar Rock, Inc.Small moleculePhase 4 / ApprovedActive
A
80/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
70/ 100
Competitive Position
95/ 100

Competitive context

21 Active assets in the Muscular Atrophy, Spinal cohort.

Asset / SponsorPhaseRating
Nusinersen
Scholar Rock, Inc.
Phase 4A
NON-REPLICATING RECOMBINANT SELF-COMPLEMENTARY (SC) ADENO-ASSOCIATED VIRUS SEROTYPE 9 (AAV9) VECTOR CONTAINING THE CDNA OF THE SURVIVAL OF MOTOR NEURON 2 (SMN2) GENE UNDER THE CONTROL OF THE HYBRID CYTOMEGALOVIRUS (CMV) ENHANCER/CHICKEN BETA-ACTIN PROMOTER (CBA)
Novartis Pharmaceuticals
Phase 4A
oav101
Novartis Pharmaceuticals
Phase 4BBB
Srk-015
Scholar Rock, Inc.
Phase 3BB
Valproic Acid
All India Institute of Medical Sciences
Phase 3BB

View all 40 →

Same molecule, other indications

Risdiplam is also rated in:

spinal muscular atrophy, type IIDormant
CCC
Indicative ·
53 / 100
View asset →
spinal muscular atrophy, type IIIDormant
CCC
Indicative ·
53 / 100
View asset →
neuromuscular diseaseDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →